
|Articles|August 1, 2017
- Pharmaceutical Executive-08-01-2017
- Volume 37
- Issue 8
Pharmaceutical Executive, August 2017 Issue (PDF)
Click the title above to open the Pharmaceutical Executive August 2017 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 8 years ago
Health Policy Problem Solver: Fumie Griegoover 8 years ago
Dealmaking in 2017: Striking a Balanceover 8 years ago
Beyond the Science: Commercial Implications From ASCO 2017over 8 years ago
News Spotlight: Pharmaover 8 years ago
Pharma’s Marijuana Makeoverover 8 years ago
The 'Hear' and Now for Pharma and Social Mediaover 8 years ago
Pressure Mounts on FDA, Pharma to Tackle Opioid Abuseover 8 years ago
Syncing Social Media With Value-Care Modelover 8 years ago
AI-based Social Listening as Aid to Pharmacovigilanceover 8 years ago
Country Report: IndonesiaNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
2
Johnson & Johnson Reaches Agreement with Trump Administration, Continues $55 Billion US-Based Investment Plan
3
Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026
4
Eli Lilly Enters $1.2 Billion Definitive Agreement to Acquire Ventyx Biosciences
5




